Cipla, a global pharmaceutical company has launched of Serroflo, its Salmeterol/Fluticasone MDI, in Germany and Sweden. With this launch, Cipla opens the door for new, highly efficient treatments in the European healthcare market. Serroflo will substantially improve the affordability of Fixed Combinations in Europe and help manage health costs for respiratory treatment. “With Serroflo we offer in Germany and Sweden an alternative which is effective and efficient and therefore brings many advantages into a market which suffers from limited resources”, said Mr. Frank Pieters, Head of Cipla Europe.
In Germany, the new product is distributed under the name “Serroflo”, whereas in Sweden the combination is launched as “Salmeterol/Fluticasone Cipla”. Serroflo and Salmeterol/Fluticasone Cipla will be available in a pMDI with HFA propellant in two strengths:
Apart from Croatia where the combination is already available under the name Duohal, Germany and Sweden are amongst the first markets where Cipla is active and others will follow. “Over the next 12-18 months we will see a series of launches throughout Europe as we know that there is a common need for high quality, affordable, reliable and thus sustainable therapy-alternatives and this is what Cipla stands for” said Mr. Subhanu Saxena, managing director and global chief executive officer, of Cipla Limited.
In Europe, about 30 million patients under 45 years suffer from asthma causing a huge burden and triggering significant disability and work loss. (ERS Lung white book 2013). The introduction of Salmeterol/Fluticasone in Germany and Sweden, is a key milestone in Cipla’s ambition to improve treatment adherence in asthma and to offer better healthcare solutions for patients irrespective of what disease they suffer from. Cipla will also bring patient engagement programmes aimed at enhancing disease knowledge and improve adherence in order to achieve good disease control. Over 50 per cent of patients of asthma in Europe have suboptimal control and the introduction of Serroflo, Salmeterol/Fluticasone Cipla will provide a new cost efficient option for many people with asthma.
Cipla is one of the worlds leading respiratory companies, with the largest range of drugs and devices approved and sold in over a 100 countries. In several markets, Cipla is prevalent in all therapy areas of respiratory medicine, and was also the first to launch several novel combinations, and drug/device combinations. Cipla aims to bring this global expertise in respiratory medicine to Europe, which will significantly impact the healthcare landscape with affordable and high quality inhalation therapy.